C12N 2710/24123
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2710/24123 (Virus like particles [vlp]) appears on 8 US grants and 9 published applications in this corpus.
Search patents in C12N- Granted patents
- 8
- Published applications
- 9
- Assignees
- 9
- Inventors
- 21
- Latest grant
- 11 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 3 |
| 2020 | 3 | 2 |
| 2021 | 0 | 0 |
| 2022 | 2 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 1 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Vaccinia viral vectors encoding chimeric virus like particles11 Mar 2025US 12,247,214 B2GeoVax, Inc.
- Vaccinia viral vectors encoding chimeric virus like particles16 Aug 2022US 11,413,341 B2GeoVax, Inc.
- Compositions and methods for generating an immune response to a tumor associated antigen22 Mar 2022US 11,278,607 B2GeoVax, Inc.
- Integral membrane protein display on poxvirus extracellular enveloped virions22 Dec 2020US 10,870,707 B2Vaccinex, Inc.
- Integral membrane protein display on poxvirus extracellular enveloped virions3 Mar 2020US 10,577,427 B2Vaccinex, Inc.
- Nanoparticle-derived vaccines against poxviruses, and methods for making and using the same12 Mar 2026US 2026/0069682 A1The United States of America as Represented by the Secretary of the Department of Health and Human S
- Vaccinia viral vectors encoding chimeric virus like particles9 Feb 2023US 2023/0040403 A1GeoVax, Inc.
- Vaccinia viral vectors encoding chimeric virus like particles17 Sep 2020US 2020/0289633 A1GeoVax, Inc.
- Integral membrane protien display on poxvirus extracellular enveloped virions9 Jul 2020US 2020/0216562 A1Vaccinex, Inc.
- Compositions and Methods for Generating an Immune Response to a Tumor Associated Antigen26 Sep 2019US 2019/0290745 A1GeoVax, Inc.
Most cited
By later US patents
- Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses3US 9,463,237 B2Baxalta Incorporated · 2016
- Compositions and methods for generating an immune response to a tumor associated antigen2US 11,278,607 B2GeoVax, Inc. · 2022
- Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses1US 10,329,583 B2Ology Bioservices, Inc. · 2019
- Vaccinia viral vectors encoding chimeric virus like particles1US 11,413,341 B2GeoVax, Inc. · 2022